Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
doi: https://doi.org/10.1101/2021.01.05.21249310
Ravikirti
1Department of General Medicine, All India Institute of Medical Sciences (AIIMS), Patna, India
Roles: Additional Professor and Head
Ranjini Roy
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Chandrima Pattadar
2Department of General Medicine, AIIMS, Patna, India
Roles: Postgraduate Trainee
Rishav Raj
3Department of General Medicine, AIIMS, Patna
Roles: Postgraduate Trainee
Neeraj Agarwal
4Department of Community and Family Medicine, AIIMS, Bibi Nagar, India
Roles: Professor and Head
Bijit Biswas
5Department of Community and Family Medicine, AIIMS, Patna, India
Roles: Senior Resident
Pramod Kumar Majhi
6Department of Pharmacology, AIIMS, Patna, India
Roles: Assistant Professor and Head
Deependra Kumar Rai
7Department of Pulmonary Medicine, AIIMS, Patna, India
Roles: Additional Professor and Head
Shyama
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Anjani Kumar
3Department of General Medicine, AIIMS, Patna
Roles: Assistant Professor
Asim Sarfaraz
9Department of Microbiology, AIIMS, Patna
Roles: Assistant Professor
Data Availability
The data can be made available by the corresponding author on rasonable request.
Posted January 09, 2021.
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial
Ravikirti, Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Bijit Biswas, Pramod Kumar Majhi, Deependra Kumar Rai, Shyama, Anjani Kumar, Asim Sarfaraz
medRxiv 2021.01.05.21249310; doi: https://doi.org/10.1101/2021.01.05.21249310
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (718)
- Anesthesia (210)
- Cardiovascular Medicine (3002)
- Dermatology (256)
- Emergency Medicine (449)
- Epidemiology (12898)
- Forensic Medicine (12)
- Gastroenterology (840)
- Genetic and Genomic Medicine (4697)
- Geriatric Medicine (432)
- Health Economics (742)
- Health Informatics (2986)
- Health Policy (1081)
- Hematology (399)
- HIV/AIDS (942)
- Medical Education (439)
- Medical Ethics (116)
- Nephrology (481)
- Neurology (4486)
- Nursing (239)
- Nutrition (657)
- Oncology (2329)
- Ophthalmology (659)
- Orthopedics (262)
- Otolaryngology (330)
- Pain Medicine (290)
- Palliative Medicine (85)
- Pathology (506)
- Pediatrics (1218)
- Primary Care Research (509)
- Public and Global Health (7072)
- Radiology and Imaging (1570)
- Respiratory Medicine (933)
- Rheumatology (454)
- Sports Medicine (390)
- Surgery (497)
- Toxicology (62)
- Transplantation (214)
- Urology (187)